At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
BI 144807drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm Open Label Study to Evaluate the Pharmacodynamics and Safety of a 4 wk Treatment With BI 144807 in Patients With Newly Diagnosed Wet Age Related Macular Degeneration (wAMD)
In Brief
A Phase 2 clinical trial evaluating BI 144807 for Wet Macular Degeneration. Completed, enrolled 14 participants across 10 sites in 3 countries.
Detailed Summary
The present trial will use an open label design to investigate the effect of BI 144807 on central 1-mm retinal thickness and presence of neovascular leakage in newly diagnosed wAMD patients. A further objective is to collect data on adverse events, vital signs, ECG and clinical laboratory parameters of BI 144807 in the same patient group.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWet Macular Degeneration
CountriesAustria, Germany, Hungary
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartJun 2014
Primary CompletionMar 2015
Study CompletionApr 2015
TodayJul 2026
First PostedApr 23, 2014
Enrollment StartJun 1, 2014
Primary CompletionMar 1, 2015
Study CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.2 years ago
Interventions
BI 144807drug
twice daily